{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:51:13Z","timestamp":1793389873345,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T00:00:00Z","timestamp":1506384000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40264-017-0602-6","type":"journal-article","created":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T09:33:32Z","timestamp":1506418412000},"page":"239-252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Can SGLT2 Inhibitors Cause Acute Renal Failure? Plausible Role for Altered Glomerular Hemodynamics and Medullary Hypoxia"],"prefix":"10.1007","volume":"41","author":[{"given":"Auryan","family":"Szalat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amichai","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mordechai","family":"Muszkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogher","family":"Khamaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Abassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel N.","family":"Heyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,26]]},"reference":[{"issue":"4","key":"602_CR1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2215\/CJN.06080616","volume":"12","author":"EJM Bommel van","year":"2017","unstructured":"van Bommel EJM, Muskiet MHA, Tonneijck L, et al. SGLT2 Inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017;12(4):700\u201310.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"602_CR2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/jdi.12644","volume":"8","author":"A Kashiwagi","year":"2017","unstructured":"Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose co-transporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8(4):416\u201327.","journal-title":"J Diabetes Investig."},{"issue":"22","key":"602_CR3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, for the EMPA-REG OUTCOME Investigators, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med."},{"issue":"7","key":"602_CR4","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, for the CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"18","key":"602_CR5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(18):323\u201334.","journal-title":"N Engl J Med."},{"issue":"1","key":"602_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11\u201326.","journal-title":"Nat Rev Nephrol."},{"issue":"Suppl 2","key":"602_CR7","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","volume":"39","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Zambon A, Rossato M, et al. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165\u201371.","journal-title":"Diabetes Care."},{"issue":"10075","key":"602_CR8","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238\u201352.","journal-title":"Lancet."},{"key":"602_CR9","unstructured":"FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm505860.htm . Accessed 16 Jun 2016."},{"issue":"4","key":"602_CR10","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.2337\/dc16-2200","volume":"40","author":"SN Heyman","year":"2017","unstructured":"Heyman SN, Khamaisi M, Rosen S, et al. Potential hypoxic renal injury in diabetics on SGLT-2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care. 2017;40(4):e40\u20131.","journal-title":"Diabetes Care."},{"issue":"1","key":"602_CR11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"EM Wright","year":"2007","unstructured":"Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32\u201343.","journal-title":"J Intern Med."},{"issue":"1","key":"602_CR12","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1152\/ajprenal.00046.2017","volume":"313","author":"BD Shepard","year":"2017","unstructured":"Shepard BD, Pluznick JL. Saving the sweetness: renal glucose handling in health and disease. Am J Physiol Renal Physiol. 2017;313(1):F55\u201361.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"602_CR13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1172\/JCI102424","volume":"30","author":"SJ Farber","year":"1951","unstructured":"Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30(2):125\u20139.","journal-title":"J Clin Invest."},{"issue":"13","key":"602_CR14","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","volume":"292","author":"XX Wang","year":"2017","unstructured":"Wang XX, Levi J, Luo Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice. J Biol Chem. 2017;292(13):5335\u201348.","journal-title":"J Biol Chem."},{"issue":"9","key":"602_CR15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/dom.12970","volume":"19","author":"A Solini","year":"2017","unstructured":"Solini A, Rossi C, Mazzanti CM, et al. SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1289\u201394.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"602_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1748-1716.2010.02147.x","volume":"200","author":"P Persson","year":"2010","unstructured":"Persson P, Hansell P, Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf). 2010;200(1):3\u201310.","journal-title":"Acta Physiol (Oxf)."},{"issue":"4","key":"602_CR17","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","volume":"28","author":"L Tonneijck","year":"2017","unstructured":"Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol. 2017;28(4):1023\u201339.","journal-title":"J Am Soc Nephrol."},{"issue":"21","key":"602_CR18","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1056\/NEJMcibr1608564","volume":"375","author":"HJ Anders","year":"2016","unstructured":"Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. N Engl J Med. 2016;375(21):2096\u20138.","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"602_CR19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2215\/CJN.03250807","volume":"3","author":"GL Bakris","year":"2008","unstructured":"Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008;3(Suppl 1):S3\u201310.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"602_CR20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587\u201397.","journal-title":"Circulation."},{"issue":"3","key":"602_CR21","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"J O\u2019Neill","year":"2015","unstructured":"O\u2019Neill J, Fasching A, Pihl L, et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309(3):F227\u201334.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"8","key":"602_CR22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"E Ferrannini","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495\u2013502.","journal-title":"Nat Rev Endocrinol."},{"key":"602_CR23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000313772","volume":"165","author":"A Chronopoulos","year":"2010","unstructured":"Chronopoulos A, Rosner MH, Cruz DN, et al. Acute kidney injury in the elderly: a review. Contrib Nephrol. 2010;165:315\u201321.","journal-title":"Contrib Nephrol."},{"key":"602_CR24","unstructured":"Diabetes management guidelines. American Diabetes Association (ADA) 2016 guidelines. http:\/\/www.ndei.org\/ADA-diabetes-management-guidelines-cardiovascular-disease-CVD-management-lipids-BP.aspx.html . Accessed May 2017."},{"issue":"2","key":"602_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2013.251","volume":"10","author":"SS Roscioni","year":"2014","unstructured":"Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol. 2014;10(2):77\u201387.","journal-title":"Nat Rev Nephrol."},{"issue":"4","key":"602_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ki.1984.185","volume":"26","author":"M Brezis","year":"1984","unstructured":"Brezis M, Rosen S, Silva P, et al. Renal ischemia: a new perspective. Kidney Int. 1984;26(4):375\u201383.","journal-title":"Kidney Int."},{"issue":"4","key":"602_CR27","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1046\/j.1523-1755.2001.00930.x","volume":"60","author":"S Rosen","year":"2001","unstructured":"Rosen S, Heyman SN. Difficulties in understanding human \u201cacute tubular necrosis\u201d: limited data and flawed animal models. Kidney Int. 2001;60(4):1220\u20134.","journal-title":"Kidney Int."},{"issue":"5","key":"602_CR28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/milmed\/99.5.371","volume":"99","author":"B Luck\u00e9","year":"1946","unstructured":"Luck\u00e9 B. Lower nephron nephrosis (the renal lesions of the crush syndrome of burns, transfusion and other conditions affecting the lower segments of the nephron). Milit Surg. 1946;99(5):371\u201396.","journal-title":"Milit Surg."},{"issue":"121","key":"602_CR29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1172\/JCI102550","volume":"30","author":"J Oliver","year":"1951","unstructured":"Oliver J, MacDowell M, Tracy A. The pathogenesis of acute renal failure associated with traumatic and toxic injury. Renal ischemia, nephrotoxic damage and the ischemic episode. J Clin Invest. 1951;30(121):1307\u201351.","journal-title":"J Clin Invest"},{"issue":"1","key":"602_CR30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.ASN.0000048852.53881.D9","volume":"14","author":"BA Molitoris","year":"2003","unstructured":"Molitoris BA. Transitioning to therapy in ischemic acute renal failure. J Am Soc Nephrol. 2003;14(1):265\u20137.","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"602_CR31","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1515\/cclm-2016-0973","volume":"55","author":"K Kashani","year":"2017","unstructured":"Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption. Clin Chem Lab Med. 2017;55(8):1074\u201389.","journal-title":"Clin Chem Lab Med."},{"issue":"10","key":"602_CR32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJM199503093321006","volume":"332","author":"M Brezis","year":"1995","unstructured":"Brezis M, Rosen S. Hypoxia of the renal medulla-its implications for disease. N Engl J Med. 1995;332(10):647\u201355.","journal-title":"N Engl J Med."},{"issue":"4\u20136","key":"602_CR33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000170341","volume":"15","author":"SN Heyman","year":"1997","unstructured":"Heyman SN, Rosen S, Brezis M. The renal medulla: life at the edge of anoxia. Blood Purif. 1997;15(4\u20136):232\u201342.","journal-title":"Blood Purif."},{"key":"602_CR34","doi-asserted-by":"crossref","first-page":"123589","DOI":"10.1155\/2013\/123589","volume":"2013","author":"SN Heyman","year":"2013","unstructured":"Heyman SN, Rosenberger C, Rosen S, et al. Why is diabetes mellitus a risk factor for contrast nephropathy? Biomed Res Int. 2013;2013:123589.","journal-title":"Biomed Res Int"},{"issue":"1","key":"602_CR35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/ki.2009.347","volume":"77","author":"SN Heyman","year":"2010","unstructured":"Heyman SN, Rosenberger C, Rosen S. Experimental ischemia\u2013reperfusion: biases and myths: the proximal vs. distal hypoxic tubular injury debate revisited. Kidney Int. 2010;77(1):9\u201316.","journal-title":"Kidney Int."},{"issue":"2","key":"602_CR36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/1440-1681.12005","volume":"40","author":"M Nangaku","year":"2013","unstructured":"Nangaku M, Rosenberger C, Heyman SN, et al. Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol. 2013;40(2):148\u201357.","journal-title":"Clin Exp Pharmacol Physiol."},{"issue":"8","key":"602_CR37","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00125-003-1155-z","volume":"46","author":"F Palm","year":"2003","unstructured":"Palm F, Cederberg J, Hansell P, et al. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia. 2003;46(8):1153\u201360.","journal-title":"Diabetologia."},{"issue":"1","key":"602_CR38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jmri.10224","volume":"17","author":"M Ries","year":"2003","unstructured":"Ries M, Basseau F, Tyndal B, et al. Renal diffusion and BOLD MRI in experimental diabetic nephropathy. Blood oxygen level-dependent. J Magn Reson Imaging. 2003;17(1):104\u201313.","journal-title":"J Magn Reson Imaging."},{"issue":"1","key":"602_CR39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.ki.5002567","volume":"73","author":"C Rosenberger","year":"2008","unstructured":"Rosenberger C, Khamaisi M, Abassi Z, et al. Adaptation to hypoxia in the diabetic rat kidney. Kidney Int. 2008;73(1):34\u201342.","journal-title":"Kidney Int."},{"issue":"12","key":"602_CR40","doi-asserted-by":"crossref","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","volume":"308","author":"AT Layton","year":"2015","unstructured":"Layton AT, Vallon V, Edwards A. Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Renal Physiol. 2015;308(12):F1343\u201357.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"1","key":"602_CR41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1681\/ASN.2005070757","volume":"17","author":"M Nangaku","year":"2006","unstructured":"Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17\u201325.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"602_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ki.2008.107","volume":"74","author":"CY Hsu","year":"2008","unstructured":"Hsu CY, Ordo\u00f1ez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int. 2008;74(1):101\u20137.","journal-title":"Kidney Int."},{"issue":"11","key":"602_CR43","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2215\/CJN.01120211","volume":"6","author":"CV Thakar","year":"2011","unstructured":"Thakar CV, Christianson A, Himmelfarb J, et al. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol. 2011;6(11):2567\u201372.","journal-title":"Clin J Am Soc Nephrol."},{"key":"602_CR44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/B978-1-4160-4252-5.50048-4","volume-title":"Critical care nephrology","author":"SN Heyman","year":"2009","unstructured":"Heyman SN, Rosen S, Rosenberger C. Critical assessment of experimental models of acute renal failure. In: Ronco C, Bellomo R, Kellum J, editors. Critical care nephrology. 2nd ed. Philadelphia: Saunders\/Elsevier; 2009. p. 237\u201350.","edition":"2"},{"issue":"1\u20132","key":"602_CR45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ddmod.2010.07.001","volume":"7","author":"SN Heyman","year":"2010","unstructured":"Heyman SN, Khamaisi M, Rosen S, et al. In vivo models of acute kidney injury. Drug Discov Today Dis Models. 2010;7(1\u20132):51\u20136.","journal-title":"Drug Discov Today Dis Models."},{"issue":"2","key":"602_CR46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ki.1986.26","volume":"29","author":"PK Jensen","year":"1986","unstructured":"Jensen PK, Steven K, Blaehr H, et al. Effects of indomethacin on glomerular hemodynamics in experimental diabetes. Kidney Int. 1986;29(2):490\u20135.","journal-title":"Kidney Int."},{"issue":"4","key":"602_CR47","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ki.1991.255","volume":"40","author":"SN Heyman","year":"1991","unstructured":"Heyman SN, Brezis M, Epstein FH, et al. Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int. 1991;40(4):632\u201342.","journal-title":"Kidney Int"},{"issue":"6","key":"602_CR48","first-page":"357","volume":"1","author":"Y Agmon","year":"1993","unstructured":"Agmon Y, Brezis M. Effects of nonsteroidal anti-inflammatory drugs upon intrarenal blood flow: selective medullary hypoperfusion. Exp Nephrol. 1993;1(6):357\u201363.","journal-title":"Exp Nephrol."},{"issue":"2","key":"602_CR49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0090-6980(90)90074-6","volume":"39","author":"D Rubinger","year":"1990","unstructured":"Rubinger D, Wald H, Scherzer P, et al. Renal sodium handling and stimulation of medullary Na-K-ATPase during blockade of prostaglandin synthesis. Prostaglandins. 1990;39(2):179\u201394.","journal-title":"Prostaglandins."},{"issue":"2","key":"602_CR50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1523-1755.2001.060002607.x","volume":"60","author":"M Goldfarb","year":"2001","unstructured":"Goldfarb M, Abassi Z, Rosen S, et al. Chronic heart failure predisposes to hypoxic outer medullary tubular injury: studies in rats. Kidney Int. 2001;60(2):607\u201313.","journal-title":"Kidney Int."},{"issue":"1","key":"602_CR51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2215\/CJN.02600607","volume":"3","author":"SN Heyman","year":"2008","unstructured":"Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol. 2008;3(1):288\u201396.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"602_CR52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0002-9343(97)00150-2","volume":"103","author":"PA McCullough","year":"1997","unstructured":"McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368\u201375.","journal-title":"Am J Med."},{"issue":"5","key":"602_CR53","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1159\/000137683","volume":"28","author":"C Rosenberg","year":"2008","unstructured":"Rosenberg C, Goldfarb M, Khamaisi M, et al. Acute kidney injury in the diabetic rat: studies in the isolated perfused and intact kidney. Am J Nephrol. 2008;28(5):831\u20139.","journal-title":"Am J Nephrol."},{"issue":"6 Pt 2","key":"602_CR54","first-page":"F1059","volume":"267","author":"M Brezis","year":"1994","unstructured":"Brezis M, Agmon Y, Epstein F. Determinants of intrarenal oxygenation. I. Effects of diuretics. Am J Physiol. 1994;267(6 Pt 2):F1059\u201362.","journal-title":"Am J Physiol."},{"issue":"3","key":"602_CR55","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/apha.12811","volume":"219","author":"M F\u00e4hling","year":"2017","unstructured":"F\u00e4hling M, Mathia S, Scheidl J, et al. Cyclosporine induces renal episodic hypoxia. Acta Physiol (Oxf). 2017;219(3):625\u201339.","journal-title":"Acta Physiol (Oxf)."},{"issue":"4644","key":"602_CR56","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.6322305","volume":"224","author":"M Brezis","year":"1984","unstructured":"Brezis M, Rosen S, Silva P, et al. Polyene toxicity in renal medulla: injury mediated by transport activity. Science. 1984;224(4644):66\u20138.","journal-title":"Science."},{"issue":"7","key":"602_CR57","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1681\/ASN.V771066","volume":"7","author":"SN Heyman","year":"1996","unstructured":"Heyman SN, Rosen S, Fuchs S, et al. Myoglobinuric acute renal failure in the rat: a role for medullary hypoperfusion, hypoxia and tubular obstruction. J Am Soc Nephrol. 1996;7(7):1066\u201374.","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"602_CR58","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0272-6386(89)80171-4","volume":"14","author":"SN Heyman","year":"1989","unstructured":"Heyman SN, Brezis M, Greenfeld Z, et al. Protective role of furosemide and saline in radiocontrast-induced acute renal failure in the rat. Am J Kidney Dis. 1989;14(5):377\u201385.","journal-title":"Am J Kidney Dis."},{"issue":"21","key":"602_CR59","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJM199411243312104","volume":"331","author":"R Solomon","year":"1994","unstructured":"Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21):1416\u201320.","journal-title":"N Engl J Med."},{"issue":"4","key":"602_CR60","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000187090","volume":"62","author":"JM Weinstein","year":"1992","unstructured":"Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron. 1992;62(4):413\u20135.","journal-title":"Nephron."},{"issue":"11","key":"602_CR61","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.111.030759","volume":"124","author":"C Briguori","year":"2011","unstructured":"Briguori C, Visconti G, Focaccio A, REMEDIAL II Investigators, et al. Renal insufficiency after contrast media administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260\u20139.","journal-title":"Circulation."},{"issue":"4","key":"602_CR62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ki.1994.132","volume":"45","author":"SN Heyman","year":"1994","unstructured":"Heyman SN, Rosen S, Epstein FH, et al. Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat kidney. Kidney Int. 1994;45(4):981\u20135.","journal-title":"Kidney Int."},{"key":"602_CR63","doi-asserted-by":"crossref","first-page":"e0158810","DOI":"10.1371\/journal.pone.0158810","volume":"11","author":"YK Chang","year":"2016","unstructured":"Chang YK, Choi H, Jeong JY, et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One. 2016;11:e0158810.","journal-title":"PLoS One."},{"issue":"4","key":"602_CR64","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/apha.12613","volume":"216","author":"SN Heyman","year":"2016","unstructured":"Heyman SN, Leibowitz D, Mor-Yosef Levi I, et al. Adaptive response to hypoxia and remote ischemia preconditioning: a new hypoxia inducible factors era in clinical medicine. Acta Physiol (Oxf). 2016;216(4):395\u2013406.","journal-title":"Acta Physiol (Oxf)."},{"issue":"9","key":"602_CR65","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15(9):853\u201362.","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"602_CR66","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ki.2009.460","volume":"77","author":"A Paliege","year":"2010","unstructured":"Paliege A, Rosenberger C, Bondke A, et al. Hypoxia-inducible factor-2\u03b1-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. Kidney Int. 2010;77(4):312\u20138.","journal-title":"Kidney Int."},{"issue":"2","key":"602_CR67","doi-asserted-by":"crossref","first-page":"176","DOI":"10.14740\/jocmr2849w","volume":"9","author":"SN Heyman","year":"2017","unstructured":"Heyman SN, Rosenberger G, Khamaisi M, et al. Increased hematocrit during sodium\u2013glucose cotransporter 2 inhibitor therapy. J Clin Med Res. 2017;9(2):176\u20137.","journal-title":"J Clin Med Res."},{"issue":"7","key":"602_CR68","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejim.2012.06.003","volume":"23","author":"CT Postma","year":"2012","unstructured":"Postma CT, Klappe EM, Dekker HM, et al. The prevalence of renal artery stenosis among patients with diabetes mellitus. Eur J Intern Med. 2012;23(7):639\u201342.","journal-title":"Eur J Intern Med"},{"issue":"6 Pt 2","key":"602_CR69","first-page":"F1063","volume":"267","author":"M Brezis","year":"1994","unstructured":"Brezis M, Heyman SN, Epstein F. Determinants of intrarenal oxygenation: 2. Hemodynamic effects. Am J Physiol. 1994;267(6 Pt 2):F1063\u20138.","journal-title":"Am J Physiol."},{"issue":"5","key":"602_CR70","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jare.2016.09.006","volume":"8","author":"K Hahn","year":"2017","unstructured":"Hahn K, Kanbay M, Lanaspa MA, et al. Serum uric acid and acute kidney injury: a mini review. J Adv Res. 2017;8(5):529\u201336.","journal-title":"J Adv Res."},{"issue":"7","key":"602_CR71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","volume":"35","author":"Y Chino","year":"2014","unstructured":"Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391\u2013404.","journal-title":"Biopharm Drug Dispos."},{"issue":"12","key":"602_CR72","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2016.159","volume":"12","author":"K Hahn","year":"2016","unstructured":"Hahn K, Ejaz AA, Kanbay M, et al. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12(12):711\u20132.","journal-title":"Nat Rev Nephrol."},{"issue":"15","key":"602_CR73","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939\u201345.","journal-title":"N Engl J Med."},{"issue":"12","key":"602_CR74","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1185\/03007995.2015.1092128","volume":"31","author":"V Perkovic","year":"2015","unstructured":"Perkovic V, Jardine M, Vijapurkar U, et al. Renal effects of canagliflozin in type 2 diabetes mellitus. Curr Med Res Opin. 2015;31(12):2219\u201331.","journal-title":"Curr Med Res Opin."},{"key":"602_CR75","doi-asserted-by":"crossref","first-page":"317507","DOI":"10.1155\/2015\/317507","volume":"2015","author":"L Zanoli","year":"2015","unstructured":"Zanoli L, Granata A, Lentini P, et al. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Sci World J. 2015;2015:317507.","journal-title":"Sci World J."},{"issue":"10","key":"602_CR76","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, Bakris G, Cariou B, DIA3004 Study Group, et al. Efficacy and safety of canagliflozin over 52\u00a0weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016\u201327.","journal-title":"Diabetes Obes Metab."},{"issue":"11","key":"602_CR77","doi-asserted-by":"crossref","first-page":"e0166125","DOI":"10.1371\/journal.pone.0166125","volume":"11","author":"H Storgaard","year":"2016","unstructured":"Storgaard H, Gluud LL, Bennett C, et al. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016;11(11):e0166125.","journal-title":"PLoS One"},{"issue":"4","key":"602_CR78","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium\u2013glucose cotransporter 2 inhibitors for type 2 diabetes. Ann Intern Med. 2013;159(4):262\u201374.","journal-title":"Ann Intern Med."},{"issue":"8","key":"602_CR79","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/dom.12917","volume":"19","author":"H Tang","year":"2017","unstructured":"Tang H, Li D, Zhang J, et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(8):1106\u201315.","journal-title":"Diabetes Obes Metab."},{"issue":"1","key":"602_CR80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33\u201359.","journal-title":"Drugs."},{"issue":"6","key":"602_CR81","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1159\/000146075","volume":"28","author":"SN Heyman","year":"2008","unstructured":"Heyman SN, Khamaisi M, Rosen S, et al. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol. 2008;28(6):998\u20131006.","journal-title":"Am J Nephrol."},{"issue":"2","key":"602_CR82","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000071289","volume":"94","author":"JT Norman","year":"2003","unstructured":"Norman JT, Stidwill R, Singer M, et al. Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action. Nephron Physiol. 2003;94(2):39\u201346.","journal-title":"Nephron Physiol."},{"issue":"2","key":"602_CR83","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.HYP.0000083341.64034.00","volume":"42","author":"LM Duke","year":"2003","unstructured":"Duke LM, Eppel GA, Widdop RE, et al. Disparate roles of AT2 receptors in the renal cortical and medullary circulations of anesthetized rabbits. Hypertension. 2003;42(2):200\u20135.","journal-title":"Hypertension."},{"issue":"3","key":"602_CR84","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jch.12263","volume":"16","author":"L Siddiqi","year":"2014","unstructured":"Siddiqi L, Hoogduin H, Visser F, et al. Inhibition of the renin-angiotensin system affects kidney tissue oxygenation evaluated by magnetic resonance imaging in patients with chronic kidney disease. J Clin Hypertens (Greenwich). 2014;16(3):214\u20138.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"5","key":"602_CR85","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.ASN.0000125614.35046.10","volume":"15","author":"K Manotham","year":"2004","unstructured":"Manotham K, Tanaka T, Matsumoto M, et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol. 2004;15(5):1277\u201388.","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"602_CR86","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ki.2015.101","volume":"88","author":"T Dreischulte","year":"2015","unstructured":"Dreischulte T, Morales DR, Bell S, et al. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and\/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int. 2015;88(2):396\u2013403.","journal-title":"Kidney Int."},{"key":"602_CR87","doi-asserted-by":"crossref","first-page":"e012690","DOI":"10.1136\/bmjopen-2016-012690","volume":"6","author":"KE Mansfield","year":"2016","unstructured":"Mansfield KE, Nitsch D, Smeeth L, et al. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open. 2016;6:e012690.","journal-title":"BMJ Open."},{"issue":"4","key":"602_CR88","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/FPC.0000000000000268","volume":"27","author":"H Zimdahl","year":"2017","unstructured":"Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genom. 2017;27(4):135\u201342.","journal-title":"Pharmacogenet Genom."},{"issue":"3","key":"602_CR89","first-page":"152","volume":"1","author":"D Dinour","year":"1993","unstructured":"Dinour D, Agmon Y, Brezis M. Adenosine: an emerging role in the control of renal medullary oxygenation? Exp Nephrol. 1993;1(3):152\u20137.","journal-title":"Exp Nephrol."},{"issue":"6 Pt 2","key":"602_CR90","first-page":"F1166","volume":"271","author":"K Gurbanov","year":"1996","unstructured":"Gurbanov K, Rubinstein I, Hoffman A, et al. Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol. 1996;271(6 Pt 2):F1166\u201372.","journal-title":"Am J Physiol."},{"issue":"1","key":"602_CR91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00134-004-2490-3","volume":"31","author":"K Sw\u00e4rd","year":"2005","unstructured":"Sw\u00e4rd K, Valsson F, Sellgren J, et al. Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. Intensive Care Med. 2005;31(1):79\u201385.","journal-title":"Intensive Care Med."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-017-0602-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-017-0602-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T03:49:49Z","timestamp":1719460189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-017-0602-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,26]]},"references-count":91,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s40264-017-0602-6","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,26]]}}}